Antiviral activities of the test compounds against TMV in vivo at 500 μg mL⁻¹.

Compounds	R	Curative activitya (%)	Protective activitya (%)	Inactivation activitya (%)
2a	Ph	72.5 ± 2.5	67.0 ± 2.1	80.1 ± 1.7
2b	4-Cl-Ph	46.4 ± 2.6	58.3 ± 0.9	53.8 ± 2.2
2c	2-Cl-Ph	52.4 ± 1.2	29.9 ± 1.0	62.3 ± 1.8
2d	3-Cl-Ph	45.3 ± 3.8	51.9 ± 2.2	59.7 ± 2.3
2e	2-F-Ph	76.2 ± 1.2	70.2 ± 1.9	87.3 ± 0.7
2f	3-F-Ph	48.5 ± 0.9	35.3 ± 2.2	60.2 ± 1.5
2g	4-F-Ph	52.3 ± 1.8	58.1 ± 0.4	58.7 ± 0.6
2h	2-Br-Ph	73.5 ± 2.1	68.8 ± 4.9	81.1 ± 1.9
2i	3-Br-Ph	26.9 ± 1.8	54.6 ± 4.4	65.3 ± 3.1
2j	4-Br-Ph	48.4 ± 0.8	61.9 ± 2.5	58.9 ± 1.7
2k	2-Py	45.6 ± 1.6	42.9 ± 1.9	66.1 ± 1.8
2l	3-NO2-Ph	74.8 ± 1.7	69.8 ± 1.6	75.3 ± 2.4
2m	3-CH3-Ph	72.6 ± 1.9	52.8 ± 0.7	69.2 ± 0.7
2n	4-CH3-Ph	30.3 ± 1.6	35.4 ± 2.9	45.3 ± 2.7
2o	3,4-di-OCH3-Ph	65.3 ± 0.8	60.2 ± 1.8	79.8 ± 2.1
2p	2,4-di-Cl-Ph	52.8 ± 2.7	40.9 ± 1.6	35.2 ± 1.9
2q	3,4-di-Cl-Ph	52.1 ± 2.0	46.2 ± 2.8	55.1 ± 3.3
2r	C3H7-Ph	27.2 ± 1.6	41.6 ± 1.9	58.1 ± 0.9
2s	2-Th	48.7 ± 4.3	32.1 ± 1.9	54.2 ± 1.7
2t	4-Py	43.9 ± 2.8	57.6 ± 1.7	56.2 ± 3.8
2u	3,4-di-CH3-Ph	49.3 ± 1.9	36.3 ± 1.8	61.2 ± 0.9
2v	2-OCH3-Ph	53.0 ± 1.8	51.1 ± 2.6	45.2 ± 1.4
Ningnanmycinb	—	53.3 ± 1.2	62.6 ± 1.3	78.3 ± 1.5

^aAverage of three replicates.

^bThe commercial antiviral agent ningnanmycin.